Clinical Trial

Analysis of Circulating Tumor Markers in Blood - ALCINA 5

Study acronym: ALCINA 5
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-02.
Trial Details
NCT Number NCT07060950
Lead Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Conditions Cancer, Lung Cancer, Non-Small Cell
Enrollment 620 participants
Start Date 2025-10
Primary Completion 2030-07 (estimated)
Study Completion 2035-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-19